60 Degrees Pharmaceuticals (NASDAQ:SXTP) stock is gaining on Monday after the specialty pharmaceutical company announced an agreement with the University of Kentucky.This agreement will have the University of Kentucky conducting a Phase IIb clinical trial of SJ733. This is a drug candidate in development by 60 Degrees Pharmaceuticals for the treatment of vivax malaria.This study will cover the use of SJ733 alongside tafenoquine to treat vivax malaria. The information from this study will also be applied to ...